AVROBIO CEO and leadership

Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.

Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies including immunotherapies and tissue-engineered products.

Multidisciplinary track record spanning; cell and gene therapies, biopharmaceuticals, medical devices and information technology, throughout their entire development cycle - discovery science, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business.

Current activities include; Chair of the BioIndustry Association (BIA) Regenerative Medicine & Cell Therapy Industry Group, Senior Editor of "Regenerative Medicine" journal, Trustee of the UK Stem Cell Foundation, Founder and Chief Executive Officer of the London Regenerative Medicine Network, Co-Chair of the Alliance for Regenerative Medicine (ARM) Cell Therapy Section, member of the Regenerative Medicine Expert Group (UK Government policy advisory group), member of the Cell Therapy Catapult Scientific Advisory Panel, member of the Canadian Networks of Centres of Excellence (NCE) Standing Selection Committee, and member of the United States Pharmacopeia (USP) Monographs - Biologics & Biotechnology Expert Committee.

Member of advisory board for a number of organisations and companies based in North America including the Strategic Advisory Board of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM) and the Ontario Institute for Regenerative Medicine.

General spokesperson for the cell therapy sector including newspaper, radio and TV interviews plus regular Twitter updates via @Prof_ChrisMason

Resides on the beautiful south coast of England and is happily married to Dr. Louise Mason [Twitter @PallMedMD] - a Consultant Physician in Palliative Medicine at a leading UK teaching hospital and a Fellow of the Royal College of Physicians.

Erik brings over 20 years of finance and biotech operating experience, including a focus on rare diseases and cell-based therapies. He was previously CFO at Summit Therapeutics, where he led the finance and investor relations functions and played a key role in multiple strategic transactions to build out the company’s U.S. and global operations. Prior to joining Summit, Erik was vice president of finance at Organogenesis Inc. He previously worked in investment banking, including as a director of healthcare investment banking with Leerink Partners. Erik began his career as an accountant with PricewaterhouseCoopers and received a BS in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.

Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.

Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies including immunotherapies and tissue-engineered products.

Multidisciplinary track record spanning; cell and gene therapies, biopharmaceuticals, medical devices and information technology, throughout their entire development cycle - discovery science, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business.

Current activities include; Chair of the BioIndustry Association (BIA) Regenerative Medicine & Cell Therapy Industry Group, Senior Editor of "Regenerative Medicine" journal, Trustee of the UK Stem Cell Foundation, Founder and Chief Executive Officer of the London Regenerative Medicine Network, Co-Chair of the Alliance for Regenerative Medicine (ARM) Cell Therapy Section, member of the Regenerative Medicine Expert Group (UK Government policy advisory group), member of the Cell Therapy Catapult Scientific Advisory Panel, member of the Canadian Networks of Centres of Excellence (NCE) Standing Selection Committee, and member of the United States Pharmacopeia (USP) Monographs - Biologics & Biotechnology Expert Committee.

Member of advisory board for a number of organisations and companies based in North America including the Strategic Advisory Board of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM) and the Ontario Institute for Regenerative Medicine.

General spokesperson for the cell therapy sector including newspaper, radio and TV interviews plus regular Twitter updates via @Prof_ChrisMason

Resides on the beautiful south coast of England and is happily married to Dr. Louise Mason [Twitter @PallMedMD] - a Consultant Physician in Palliative Medicine at a leading UK teaching hospital and a Fellow of the Royal College of Physicians.

Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.

Erik brings over 20 years of finance and biotech operating experience, including a focus on rare diseases and cell-based therapies. He was previously CFO at Summit Therapeutics, where he led the finance and investor relations functions and played a key role in multiple strategic transactions to build out the company’s U.S. and global operations. Prior to joining Summit, Erik was vice president of finance at Organogenesis Inc. He previously worked in investment banking, including as a director of healthcare investment banking with Leerink Partners. Erik began his career as an accountant with PricewaterhouseCoopers and received a BS in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.

Board of Directors, Tecogen, Inc. (TGEN);

Board of Directors, Armagen;

Board of Directors, American DG Energy (ADGE);

Board of Directors, Massachusetts Biotechnology Association;

Board of Directors, Healthcare Businesswomen's Association, Boston Chapter;

Founding Member, Boston BioPharma Executive Council